VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

NCT04702425 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

37

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Non-Hodgkin Lymphoma (NHL)
Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)

Interventions

DRUG: VOB560
DRUG: MIK665

Sponsor

Novartis Pharmaceuticals